Navigation Links
WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
Date:10/26/2007

SHANGHAI, China, Oct. 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that it has been ranked the 28th in the Deloitte Technology Fast 50 China program, a ranking of the 50 fastest growing technology companies in China. The awards ceremony was held in the JW Marriott Hotel Shanghai at Tomorrow Square, Shanghai on October 25.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The Deloitte Technology Fast 50 China program ranks leading companies in Technology, Media and Telecom (TMT) sectors based on their average revenue growth rates over the last three years. Given China's rapid economic growth, the strong development of the TMT industry, the government advocating technology innovation and the appetite of local and overseas venture capital for fast growing technology companies, this year's revenue growth requirement for winning has substantially increased. As a result, more than half of the winners are the first time winners and only one of the top 10 winners is a previous winner.

Ranked the 22nd, 27th and 28th in 2005, 2006 and 2007, respectively, WuXi PharmaTech is one of the nine companies to win the award for three consecutive years.

''We are pleased to be recognized by Deloitte for our accomplishments for the third time," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "As the whole industry sector enjoys remarkable growth, WuXi PharmaTech has grown from a small start-up to a New York Stock Exchange listed company. I am very proud that we still can maintain our relative rank on the list, and I would like to take this opportunity to thank our customers for their strong support and employees for their dedication and hard work," continued Dr. Li.

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, toxicology, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com.

For more information, please contact:

Sherry Shao

Tel: +86 (21) 5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UW-Madison MBA program ranked among best for investment return
2. Madison top-ranked In Digital Cities Survey
3. Oshkoshs Pierce Security Vehicle Ranked in top 100 Technological Innovations for 2003
4. Wisconsin Companies Ranked Top in Nation in IT
5. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
6. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
7. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
8. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
9. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
10. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
11. Use of Novel FlashPlate Technology to Measure cAMP Accumulation in Chinese Hamster Ovary Cells Expressing Human -2 Adrenoreceptors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):